NILESH RANJAN

Employment

• Health City CONSULTANT
  2024 - Present
• North east cancer hospital and research institute CONSULTANT
  2023 - 2024
• Assam Cancer Care Foundation CONSULTANT
  2022 - 2023
• Tata Memorial Centre Senior Resident
  2021 - 2022

Education

• All India Institute of Medical Sciences - Patna MBBS
  2012 - 2017

Projects & Funding

Projects & funding information is unavailable.

Publications (14)

• Cumulative gastrointestinal adverse events in EMBRACE-I: comparative evaluation of CTCAE vs. MOSES methods in predicting the impact of incident vs. persistent adverse events on quality of life
  Radiotherapy and Oncology 2026 DOI: 10.1016/j.radonc.2026.111489
  +Save
• Normal tissue complication probability models for gastrointestinal toxicity after adjuvant (chemo)radiotherapy for cervical cancer in the PARCER trial
  Radiotherapy and Oncology 2026 DOI: 10.1016/j.radonc.2026.111444
  +Save
• 1131 Normal Tissue Complication Probability models for gastrointestinal toxicity after adjuvant (chemo) radiotherapy for cervical cancer in the PARCER trial
  Radiotherapy and Oncology 2025 DOI: 10.1016/s0167-8140(25)00302-0
  +Save
• 936 Intensity Modulated Proton Therapy for pelvic RT based on normal tissue complication probability estimates of persistent GI toxicity in PARCER trial.
  Radiotherapy and Oncology 2025 DOI: 10.1016/s0167-8140(25)04413-5
  +Save
• Cumulative gastrointestinal adverse events in EMBRACE-I: Comparative evaluation of CTCAE vs. MOSES methods in predicting the impact of incident vs. persistent adverse events on quality of life
  2025 DOI: 10.2139/ssrn.5829403
  +Save
• 2412: DVH-AUC predictors of incidence & prevalence of late GI toxicity: Secondary analysis of PARCER trial
  Radiotherapy and Oncology 2024 DOI: 10.1016/s0167-8140(24)02620-3
  +Save
• Longitudinal Costs of Image-Guided Intensity-Modulated Radiation Therapy Versus Three-Dimensional Conformal Radiation: Lessons From Phase III PARCER Trial for Shaping Resource-Stratified Guidelines in Low- and Middle-Income Countries
  JCO Global Oncology 2024 DOI: 10.1200/GO.23.00478
  +Save
• OC-0606 Severity and time-weighted gastrointestinal morbidity in cervix cancer: EMBRACE analysis with MOSES
  Radiotherapy and Oncology 2023 DOI: 10.1016/s0167-8140(23)08662-0
  +Save
• Late toxicity within a Phase III clinical trial of IG-IMRT in cervix cancer (PARCER): Reanalysis with time weighted adverse event reporting (MOSES)
  Radiotherapy and Oncology 2022 DOI: 10.1016/j.radonc.2022.10.013
  +Save
• Months and Severity Score (MOSES) in a Phase III trial (PARCER): A new comprehensive method for reporting adverse events in oncology clinical trials
  eClinicalMedicine 2022 DOI: 10.1016/j.eclinm.2022.101390
  +Save